Lazaroids and Neuroprotection: What Benefit?

Maria Rosaria Carratù*

Department of Biomedical Sciences and Human Oncology, "Aldo Moro" University of Bari, Italy

Submission: February 14, 2017; Published: February 22, 2017

*Corresponding author: Maria Rosaria Carratù, Department of Biomedical Sciences and Human Oncology, "Aldo Moro" University of Bari, Piazza Giulio Cesare 11, 70124 Bari, Italy, Email: mariarosaria.carratu@uniba.it

Abbreviations: SCI: Spinal Cord Injuries; LP: Lipid Peroxidation; MP: Methylprednisolone

Editorial

Acute spinal cord injuries (SCI) are among the most devastating traumatic situations and are responsible for high morbidity and mortality rates. The consequences include motor and sensory impairment as well as perturbations of intestinal, urinary and sexual functioning [1]. Chronic neuropathic pain is a common consequence of SCI, develops over time and negatively impacts quality of life, often leading to substance abuse and depression [2]. Many factors are involved in the pathogenesis of SCI. After the initial mechanical injury, the secondary lesions arise and involve a variety of processes leading to expansion of the primary lesion. These phenomena include inflammation, oedema, ischemia, electrolytic imbalance, glutamate-induced excitotoxicity, apoptosis, lipid peroxidation (LP) [3]. Although many key players are involved in the secondary cascade of events, reactive oxygen-induced LP appears to play a critical role. Therefore, a neuroprotective pharmacologic strategy would aim at antagonizing oxygen radical-induced LP in a safe and effective manner. Indeed, the pharmacological therapy of SCI is actually unsatisfactory. Modest benefits from the treatment with a high dose regimen of methylprednisolone (MP), if applied early, could improve spinal cord tissue survival, thus preserving the necessary anatomic substrate for functional recovery to take place [4,5].

The rationale for its use lays, at least in part, on the MP ability to limit the propagation of LP chain reactions throughout the phospholipid bilayer [6], although anti-inflammatory effects may play some role as well [4]. However, this approach is somewhat controversial on the basis of a high incidence of serious adverse effects due to immunosuppressant and metabolic effects of MP with a significantly greater risk among patients treated with high doses [7]. Based on the LP hypothesis, antioxidant drugs were hopefully tested in the attempt to find a valid therapeutic option of proven efficacy and safety. In particular, a family of steroid compounds, 21-aminosteroids or "lazaroids", were developed. Although these compounds derive from glucocorticoids, they lack glucocorticoid activity, while simultaneously retaining a propensity for cell membrane localization [8]. In fact, lazaroids were shown to scavenge lipid peroxyl radicals and to inhibit iron-dependent lipid peroxidation. In particular, tirilazad mesylate was selected for clinical development, as a neuroprotective agent with the expectation to benefit from a more potent LP inhibitor devoid of the glucocorticoid receptor-mediated effects that limit the clinical utility of high-dose MP.

Tirilazad mesylate was extensively studied in animal models for the prevention of neuronal damage due to head trauma, subarachnoid hemorrhage, spinal cord injury and stroke. In these systems, tirilazad can inhibit post-traumatic LP and associated pathophysiological events, thus promoting neurological recovery after acute insult. A limited activity on mechanical hypersensitivity was observed in a model of chronic SCI-induced neuropathic pain in which oxidation damage seems to play a relevant role [9]. Results of NASCIS clinical trials in SCI patients showed some evidence of efficacy comparable to MP in the absence of steroid-related side effects [10]. Hence, this non-glucocorticoid 21-aminosteroid would be safer than MP for extension of dosing beyond the temporal limit used in clinical trials. Based on the role of reactive oxygen or oxygen-radical-induced LP in the pathophysiology of post-traumatic spinal cord degeneration, and evidence of benefits from antioxidant compounds with neuroprotective activity like MP and tirilazad, other compounds with scavenger activity were developed. One of the most critical ROS in acute SCI appears to be peroxynitrite [11,12] which is formed from the combination of superoxide and nitric oxide radicals [13,14]. In this regard, penicillamine and...
Tempol is prototypical scavenger of peroxynitrite, and both are neuroprotective in cell culture and in vivo models of acute CNS injury.

Another promising antioxidant-based approach concerns the design of dual inhibitors of LP and neuronal NOS such as BN-80933 that has been reported to attenuate post-traumatic and post-ischemic degeneration in in vivo models [15]. It is clear that degeneration of the spinal cord following injury is caused by a multi-factorial secondary process; hence no pharmacologic approach based on the use of a single drug can actually promote neurological recovery. Indeed, this is the case of MP or tirilazad, both limiting the propagation of LP chain reactions throughout the phospholipid bilayer, regardless of the additional anti-inflammatory property of MP. The benefit of MP is questioned, with concerns regarding its safety. In this regard, tirilazad that is devoid of the typical side effects of steroid therapy could more safely and efficiently inhibit post-traumatic LP compared to high dose MP. However, the pharmacological scenario emerging from a review of the literature is more extensive and comprises other compounds. For instance, anti-inflammatory agents showed benefits in humans or animals, many inhibitors of apoptosis showed benefits in in vitro studies or in animal models, GM-1 was not more effective than MP, naloxone did not show benefits [4,5]. Thus, there is a need to find new neuroprotective or neurorestorative treatments, possibly targeting more than one mechanism. Such a goal would appear pursuable through co-administration of different agents. However, this raises a significant challenge mainly in terms of ethical and regulatory affairs as masterfully underlined by Hall and Springer [4] in their exhaustive reappraisal.

**References**